Bone Biologics (NASDAQ:BBLG) Shares Up 0.1% – What’s Next?

Bone Biologics Corp. (NASDAQ:BBLG)’s stock price rose 0.1% on Friday. The company traded as high as $0.4811 and last traded at $0.4754. Approximately 20,624 shares traded hands during trading, a decline of 93% from the average session volume of 299,670 shares. The stock had previously closed at $0.4750.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Bone Biologics in a report on Friday, July 24th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, Bone Biologics has a consensus rating of “Sell”.

Bone Biologics Price Performance

The company has a market cap of $1.31 million, a PE ratio of -0.35 and a beta of 0.90. The business has a 50 day moving average of $0.65 and a 200 day moving average of $1.06.

Bone Biologics (NASDAQ:BBLG) last announced its earnings results on Friday, August 14th. The company reported ($0.43) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.04). Sell-side analysts forecast that Bone Biologics Corp. will post -1.23 EPS for the current fiscal year.

About Bone Biologics

Bone Biologics Corporation is a medical device and biotechnology company focused on developing regenerative products for bone repair and reconstruction. Its work centers on NELL-1, a recombinant protein intended to stimulate bone formation and support the healing of skeletal defects.

The company is developing NELL-1-based bone graft substitutes and delivery systems, including applications designed for spinal fusion and other orthopedic procedures. These products are intended to provide alternatives or complements to traditional bone graft materials by promoting the body’s own bone-regeneration processes.

Bone Biologics is a development-stage company, and its technologies remain subject to clinical, regulatory and commercial development requirements.